Zymeworks Inc (ZYME)
14.14
+0.56
(+4.12%)
USD |
NASDAQ |
Dec 20, 16:00
14.11
-0.03
(-0.21%)
After-Hours: 20:00
Zymeworks Enterprise Value: 676.73M for Dec. 20, 2024
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Pfizer Inc | 206.32B |
| Ligand Pharmaceuticals Inc | 1.945B |
| Cellectar Biosciences Inc | -10.95M |
| Revance Therapeutics Inc | 570.21M |
| CNS Pharmaceuticals Inc | -0.5609M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -29.85M |
| Revenue (Quarterly) | 16.00M |
| Total Expenses (Quarterly) | 50.25M |
| EPS Diluted (Quarterly) | -0.39 |
| Profit Margin (Quarterly) | -186.6% |
| Earnings Yield | -10.54% |
| Normalized Earnings Yield | -9.245 |